Search clinical trials for: S768I

Total 6 results

Qingdao Central Hospital

Recruiting

Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer

PFS

China
ArriVent BioPharma, Inc.

Recruiting

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Non-Small-Cell Lung Cancer | Metastatic Non-Small-Cell Lung Cancer | Advanced Non-Small-Cell Lung Cancer | EGFR P-Loop and Alpha C-Helix Compressing | EGFR PACC | EGFR Uncommon Mutations

United States, Australia, Spain, Hong Kong, China, Taiwan, Japan, United Kingdom, Canada, Italy, Greece, Singapore, France, South Korea, Turkey (Türkiye), Thailand, Malaysia
BlossomHill Therapeutics

Recruiting

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (SOLARA)

NSCLC (Advanced Non-small Cell Lung Cancer)

Hong Kong, United States, Australia, Taiwan, Singapore, Malaysia, Canada, Japan, South Korea
Sun Yat-sen University

Recruiting

Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations (IcomBine)

Non-small Cell Lung Cancer Metastatic | EGFR G719X | EGFR L861Q | EGFR S768I

China
Chongqing University Cancer Hospital
Army Specialty Medical Center; The Second Affilicated Hospital of Chongqing...

Recruiting

First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation

Non-small Cell Lung Cancer | EGFR G719X | EGFR L861Q | EGFR S768I

China

Search clinical trials for: S768I

This is a preview